کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
988845 | 935370 | 2010 | 6 صفحه PDF | دانلود رایگان |
IntroductionGeographic transferability of model-based cost–effectiveness results may facilitate and shorten the reimbursement process of new pharmaceuticals. This study provides a real world example of transferring a cost–effectiveness study of trastuzumab for the adjuvant treatment of HER2-positive early breast cancer from the United Kingdom to The Netherlands.MethodsThree successive steps were taken. Step 1: Collect available information with regard to the original model, and assess transferability using existing checklists. Step 2: Adapt transferability-limiting factors. Step 3: Obtain a country-specific estimate of cost–effectiveness.ResultsThe structure of the UK model was transferable, although some of the model inputs needed adaptation. From a health-care perspective, the Dutch estimate amounted to €5828/quality-adjusted life-year gained. From a societal perspective, the incremental cost–effectiveness ratio was dominant.ConclusionTransferability of a model-based UK-study in three steps proved to be an efficient method to provide an early indication of the cost–effectiveness of trastuzumab and has led to the provisional reimbursement of the treatment.
Journal: Value in Health - Volume 13, Issue 4, June–July 2010, Pages 375-380